This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Asacol Dosing Study for Active Ulcerative Colitis

This study has been completed.
Procter and Gamble
Information provided by:
University of Washington Identifier:
First received: September 15, 2005
Last updated: February 13, 2008
Last verified: February 2008
We, the investigators at University of Washington, plan on evaluating the effect of open label Asacol at a dose of 4.8 grams/day divided BID (twice per day) or TID (three times per day) on its ability to induce remission in patients with mild to moderately active ulcerative colitis. We hypothesize that both regimens will have the same efficacy and no difference in side effects.

Condition Intervention Phase
Ulcerative Colitis Drug: Asacol (mesalamine) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis

Resource links provided by NLM:

Further study details as provided by University of Washington:

Primary Outcome Measures:
  • Proportion of patients in each arm that have presence of clinical remission by week 12, as defined by UCAI score of less than or equal to 4. [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Proportion of patients in each arm who respond to therapy as measured by a reduction in UCAI score of greater than or equal to 4. [ Time Frame: 12 weeks ]
  • Proportion of patients in each arm who have improvement in Inflammatory Bowel Disease Questionnaire (IBDQ) scores [ Time Frame: 12 weeks ]
  • Time to clinical response [ Time Frame: 12 weeks ]
  • Self reported patient satisfaction [ Time Frame: 12 weeks ]
  • Patient compliance based on pill count [ Time Frame: 12 weeks ]
  • Time to failure [ Time Frame: 12 weeks ]

Enrollment: 7
Study Start Date: June 2003
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Asacol 6 tablets BID (4.8 grams/day)
Drug: Asacol (mesalamine)
Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
Other Name: Mesalamine
Active Comparator: 2
Asacol 4 tablets TID (4.8 grams/day)
Drug: Asacol (mesalamine)
Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
Other Name: Mesalamine

  Show Detailed Description


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to provide consent
  • Age older than 18 years and younger than 80 years
  • Confirmed diagnosis of ulcerative colitis by endoscopic or radiologic evaluation at least 4 weeks prior to randomization
  • Active ulcerative colitis at time of screening (UCAI > 4 <12)
  • Receiving stable doses of medications at least 4 weeks prior to receiving the first dose of study drug
  • Agree to use of an adequate form of contraception throughout the study period for sexually active males and females of child-bearing potential
  • Able to comply with protocol requirements
  • Subjects may not be on any form of corticosteroids, immunosuppressives or anti-tumor necrosis factor (TNF) therapy

Exclusion Criteria:

  • Critically ill
  • Risk factors for toxicity to Asacol, including pre-existing hepatic disease (biopsy-proven cirrhosis, chronic active hepatitis, or serum aspartate aminotransferase, bilirubin, or alkaline phosphatase concentrations at least twice the upper limit of normal except for patients with the diagnosis of primary sclerosing cholangitis, a liver disease which occurs in patients with ulcerative colitis), renal dysfunction (serum creatinine concentration greater than 1.7 mg per deciliter [150mmol per liter]). Patients with primary sclerosing cholangitis (PSC), a liver disease that is often associated with ulcerative colitis, will be allowed to participate in the study if their liver function tests have been stable for at least 4 weeks. Previous studies have not shown any detrimental effects of Asacol on PSC.
  • Systemic infections
  • Pregnancy or a desire to become pregnant
  • High alcohol consumption (more than seven drinks per week)
  • Known hypersensitivity to Asacol
  • Estimated survival of less than one year
  • Unwilling to comply with the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00194818

United States, Washington
University of Washington Medical Center
Seattle, Washington, United States, 98195
Sponsors and Collaborators
University of Washington
Procter and Gamble
Principal Investigator: Scott D Lee, MD University of Washington
  More Information

Responsible Party: Scott D. Lee, MD, University of Washington Identifier: NCT00194818     History of Changes
Other Study ID Numbers: 04-1694-A 01
Study First Received: September 15, 2005
Last Updated: February 13, 2008

Additional relevant MeSH terms:
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on September 19, 2017